Partner Nate Lacktman was quoted in a Fierce Healthcare article, “In Texas, Hurricane Harvey Response Efforts Provide a ‘Defining Moment’ for Telehealth,” about how Houston residents have been able to secure health care through telemedicine in the wake of Hurricane Harvey. The natural disaster presented a unique way to showcase telemedicine. Lacktman expects public and government officials will increasingly appreciate telemedicine during natural disasters and predicts hospitals will begin integrating telehealth services into their disaster plans.
“The accessibility of medical and mental health services via victims’ smartphones cannot be understated,” Lacktman said. “For millions of people, the smartphone is their lifeline and can serve as the tether to reach doctors and medical professionals, even when the local power lines are down,” he said.
“The accessibility of medical and mental health services via victims’ smartphones cannot be understated,” Lacktman said. “For millions of people, the smartphone is their lifeline and can serve as the tether to reach doctors and medical professionals, even when the local power lines are down,” he said.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”